Roundup Settlement Opt-Out Deadline Is Days Away, But The Legal Fight Is Far From Over

If you have ever used Roundup weed killer, your legal rights could be at stake. You have until June 4, 2026, to protect them.

Bayer’s proposed $7.25 billion Roundup settlement was meant to resolve one of the largest litigations in American history. Instead, it has led to legal objections, efforts to move the case to federal court and serious questions about whether the deal is constitutional or fair to the cancer patients it is supposed to help.

With the opt-out deadline approaching, millions of people are caught in a legal battle they might not even realize is happening.

What Is the Roundup Settlement?

Bayer proposed the $7.25 billion class action settlement in February 2026 to resolve tens of thousands of Roundup lawsuits filed by people who say they developed non-Hodgkin lymphoma (NHL) after using the popular glyphosate-based weed killer. A Missouri judge granted preliminary approval on March 4, 2026, setting the stage for a final approval hearing on July 9, 2026.

According to the settlement, people currently diagnosed with NHL could receive between $6,000 and $165,000 or more, depending on their exposure history, age at diagnosis and type of cancer. The strongest cases, such as those with occupational exposure, diagnosis before age 60 and aggressive NHL, could have an average settlement payout of $165,000. Many other cases might receive as little as $20,000.

For context, a Georgia jury awarded a single plaintiff more than $2 billion in a Roundup verdict last year.

See if You Qualify for a Lawsuit Our Partners

Our Trusted Legal Partners

Drugwatch partners with trusted law firms to help you take legal action. After submitting the form, one of Drugwatch's partners will contact you for a free case review.

Diagnosed with cancer after exposure to Roundup?

Get A Free Case Review

Critics Are Calling It a “Sweetheart Deal”

From the beginning, legal experts and competing plaintiffs’ attorneys criticized the settlement, saying it was designed to help Bayer rather than cancer victims. On May 21, 2026, attorney Ashley Keller and the Tennessee firm Frazer PLC formally objected in Missouri’s Circuit Court of the City of St. Louis, calling the deal “grossly inadequate and unfair.”

The numbers reveal some of the issues. The plaintiffs’ attorneys who negotiated the deal with Bayer could receive $675 million in legal fees. At the same time, many farmers, landscapers and homeowners who developed cancer would get only a small portion of what their cases might be worth in court. The plaintiffs’ attorneys who oppose the settlement see this disparity as unjust to cancer victims. The objection also pointed out that Bayer could keep selling Roundup under the settlement.

​The next day, Keller filed a “notice of removal” to move the case from Missouri state court to federal court, aiming for U.S. District Judge Vince Chhabria in California, who has overseen the national Roundup litigation since 2016. Chhabria has publicly called the deal “filthy,” “mind-boggling,” and “legally problematic,” but he does not have authority over state court cases. Critics say this is intentional. They argue the settlement was filed in a favorable Missouri court to avoid the tougher scrutiny it would get in federal court, calling it a “liability-management scheme” pushed through the courts.

The attempt to transfer the case uses a new legal argument. Since Monsanto and the settling attorneys both want the deal approved, the objecting cancer victims are seen as the real opposing parties, almost like defendants. Legal experts say this argument is creative but may not work. An attorney who helped craft the deal with Bayer has called it a “baseless delay tactic.”

The Unprecedented “Futures” Problem and Why It May Be Unconstitutional

This is where the settlement enters truly new territory.

Most class action settlements only affect people who are already sick and know they have a claim. This one goes much further. It creates a “futures” subclass that automatically covers anyone in the United States exposed to Roundup or other glyphosate-based weed killers before February 17, 2026. This includes children and could even include people who have not yet been born.

If any of these people are later diagnosed with NHL, they would be limited by the settlement’s compensation caps unless they opt out by June 4, 2026.​

People who have no idea they might one day develop cancer are being asked to make a permanent legal decision now or lose their right to sue. The objection filings describe the opt-out process as “comically difficult” for injured parties to handle and argue that the whole structure is unconstitutional:

“The class seeks to bind a group of millions upon millions of people, many who have not been conceived and millions who are children, to the terms of the settlement via a so-called ‘futures’ subclass reaching anyone who ‘saw’ anyone using Roundup. Such a class is unconstitutional and unprecedented in the annals of US jurisprudence.”​

The U.S. Constitution’s due process guarantees require real notice and a fair chance to protect one’s rights. It is hard to see how someone who does not have cancer yet, and might not for another 20 years, could have received meaningful notice of a deadline that ends so soon.

A Supreme Court Decision Looms and the Timing Is No Coincidence

Layered on top of all of this is a pending U.S. Supreme Court decision that could reshape the entire litigation.

The Court heard oral arguments last month in Monsanto v. Durnell. At the heart of the case is whether federal law — specifically the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) — preempts state court juries from holding Monsanto liable for failing to warn about cancer risk when the EPA has not required such a warning. The EPA maintains that glyphosate is “unlikely” to be carcinogenic, a position sharply at odds with the World Health Organization’s cancer research agency, which classified it as a probable human carcinogen in 2015. If the Supreme Court sides with Monsanto, it could effectively shut down future failure-to-warn lawsuits — the legal theory that produced billion-dollar verdicts against Bayer in recent years.

Supporters of the settlement have used Durnell as leverage, telling plaintiffs that opting out is too risky because of a possible negative ruling. But there is a problem: The opt-out deadline is June 4, and the Supreme Court decision is not expected until late June or early July, after the deadline has already passed.

People are being asked to make a final legal decision without knowing the result of the most important development in the whole case. That is not a coincidence. It’s a pressure tactic.

What Should You Do?

If you or someone you love has been exposed to Roundup and has been diagnosed with non-Hodgkin lymphoma, the June 4 deadline is critical. You have three choices:

1. Stay in the settlement. You give up your right to sue Bayer independently, but may receive compensation if the settlement is finally approved.
2. Opt out. You preserve your right to file your own lawsuit, but you receive nothing from this settlement. If the Supreme Court rules against plaintiffs, your case could become significantly harder to pursue.
3. Object. You can formally object to the settlement terms before the June 4 deadline, which allows you or your attorney to be heard at the July 9 final approval hearing. You cannot both opt out and object.

Because of the serious constitutional questions about this settlement and the unusual way it tries to include people who have not yet been diagnosed, anyone who might be affected should talk to an attorney experienced in Roundup cases before June 4.

The confusion around this settlement is not accidental. People already fighting cancer should not have to deal with a complicated opt-out process while racing against the clock and waiting for a Supreme Court decision that could change everything.